Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

Technology appraisal guidance
Reference number: TA661
Published: 25 November 2020

History

Declaration of interests

Register of interests (PDF 261 KB)

Published:

29 October 2021

Expected publication

Equality Impact Assessment (Guidance development) (PDF 158 KB)

Published:

25 November 2020

Final draft guidance: 2

Final draft guidance: 2
Committee papers (PDF 2.36 MB)

Published:

22 October 2020
Public committee slides (PDF 1.02 MB)

Published:

22 October 2020
Final appraisal document 2 (PDF 281 KB)

Published:

22 October 2020

Draft guidance

Draft guidance
Appraisal consultation document (PDF version) (PDF 305 KB)

Published:

15 January 2020
Committee papers (PDF 8.81 MB)

Published:

15 January 2020
Public committee slides (PDF 1.33 MB)

Published:

15 January 2020
Appraisal consultation document (online commenting)

Invitation to participate

Final scope (PDF 183 KB)

Published:

21 March 2019
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 204 KB)

Published:

21 March 2019
Equality impact assessment (Scoping) (PDF 122 KB)

Published:

21 March 2019
Final stakeholder list (PDF 187 KB)

Published:

21 March 2019

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Draft scope post referral (PDF 330 KB)

Published:

19 July 2017
Draft matrix post referral (PDF 260 KB)

Published:

19 July 2017